Long-term remission after allogeneic hematopoietic stem cell transplantation for refractory cutaneous T-cell lymphoma

Keyphrases

• Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) 100%
• Cutaneous T-cell Lymphoma 100%
• Long-term Remission 100%
• Therapeutic Potential 66%
• Young Patients 66%
• Sustained Remission 66%
• Complete Remission 66%
• Tumor Effect 66%
• Marrow 33%
• Tumor Stage 33%
• Clinical Remission 33%
• Poor Prognosis 33%
• Recurring 33%
• CD34 33%
• Graft-versus-host Disease (GvHD) 33%
• Hematologic 33%
• Disease-free 33%
• Malignant T Cells 33%
• Hematopoietic Stem Cell Transplantation 33%
• Immune Defense 33%
• Cell Processes 33%
• Refractory Tumors 33%
• Natural History of Disease 33%
• Mycosis Fungoides 33%
• Allogeneic Graft 33%
• Neoplastic Disorders 33%
• Peripheral Blood Stem Cell Transplantation 33%
• Total Body Irradiation 33%
• HLA-matched Donor 33%
• Unrelated Donor Transplantation 33%
• Histological Remission 33%
• Limited Cutaneous 33%
• Cytoreductive Chemotherapy 33%
• Allogeneic HLA 33%

Medicine and Dentistry

• Diseases 100%
• Allogeneic Hematopoietic Stem Cell Transplantation 100%
• Cutaneous T Cell Lymphoma 100%
• Graft Versus Tumor Effect 50%
• Immunity 25%
• Recurrent Disease 25%
• Chemotherapy 25%
• Cancer Staging 25%
• Hematopoietic Stem Cell Transplantation 25%
• Allograft 25%
• Mycosis fungoides 25%
• Peripheral Blood Stem Cell Transplantation 25%
• Whole Body Radiation 25%
• T Cell 25%
• Graft Versus Host Reaction 25%